TY  - GEN 
AU  - Morata, L.
AU  - Aguado, J.M.
AU  - Salavert, M.
AU  - Pasquau, J.
AU  - Míguez Rey, Enrique
AU  - Muñoz, P.
AU  - Rosselló, I.
AU  - Almirante, B.
PY  - 2022
SN  - 2632-1823
UR  - http://hdl.handle.net/20.500.11940/20845
AB  - Objectives: Dalbavancin is approved for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) in adults. Its unique pharmacokinetic properties allow daily dosing to be avoided. The objective was to describe the sociodemographic...
LA  - eng
TI  - Dalbavancin in clinical practice in Spain: A 2 year retrospective study
DO  - 10.1093/jacamr/dlac120
KW  - AS Coruña
KW  - CHUAC
KW  - INIBIC
VL  - 4
ER  -